(3-206) Postmarket Safety Comparison of Sotagliflozin vs. SGLT2 Inhibitors: FDA-Labeled Important & Most Frequent Adverse Reactions vs FAERS Reports

Monday, December 8, 2025

12:00 PM - 1:00 PM

Location: Bayside A, Level 1

Pharmacy School: Notre Dame of Maryland University School of Pharmacy
Pharmacy School Location: Maryland

Co-Author(s): Ai-Chen (Jane) Ho

Primary Author(s)

Vincent Englebert T. Sy-siong, BSPharm

Pharmacy Student
Notre Dame of Maryland University